cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Editas Medicine Inc
91 own
56 watching
Current Price
$5.46
$-0.14
(-2.5%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
472.51M
52-Week High
52-Week High
11.91000
52-Week Low
52-Week Low
5.28500
Average Volume
Average Volume
1.62M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization472.51M
icon52-Week High11.91000
icon52-Week Low5.28500
iconAverage Volume1.62M
iconDividend Yield--
iconP/E Ratio--
What does the Editas Medicine Inc do?
Developing gene editing therapies based on CRISPR/Cas9 technology.
Read More
How much money does Editas Medicine Inc make?
News & Events about Editas Medicine Inc.
Globe Newswire
10 months ago
CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting ...
Globe Newswire
10 months ago
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant First two RUBY patients achieved normal levels of total hemoglobin and fetal hemoglobin of >40% at 5 months and maintained these ...
Globe Newswire
11 months ago
Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress (EHA) and in a Company-sponsored webinar On track to dose 20 total patients by year-end in the RUBY trial First patient in EDIT-301 EDITHAL trial for TDT dosed ...
Globe Newswire
12 months ago
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-endCAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) ...
Zolmax
1 year ago
Shares of Editas Medicine, Inc. (NASDAQ:EDIT Get Rating) have received an average recommendation of Hold from the sixteen research firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, seven have issued a hold...
Frequently Asked Questions
Frequently Asked Questions
What is Editas Medicine Inc share price today?
plus_minus_icon
Can Indians buy Editas Medicine Inc shares?
plus_minus_icon
How can I buy Editas Medicine Inc shares from India?
plus_minus_icon
Can Fractional shares of Editas Medicine Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Editas Medicine Inc stocks?
plus_minus_icon
What is today’s traded volume of Editas Medicine Inc?
plus_minus_icon
What is today’s market capitalisation of Editas Medicine Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Editas Medicine Inc?
plus_minus_icon
What percentage is Editas Medicine Inc down from its 52-Week High?
plus_minus_icon
What percentage is Editas Medicine Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.46
$-0.14
(-2.5%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00